- Aktuelle Seite:
-
Home
-
Substitutionsmittel
-
Buprenorphin
- Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment.
Buprenorphin-Depot: Annäherung an das Äquivalenzprinzip in Haft - Besondere Eignung von Buvidal® zur Substitutionstherapie in der JVA
Mannheim/Lund, 13.12.2019 – Die 4. Gefängnismedizintage am 5. und 6. Dezember 2019 in Frankfurt stießen auf reges Interesse bei Medizinern und Pflegekräften im Vollzug. Dem von der Camurus GmbH unterstützten Symposium „Das Depot – neue Wege in der Behandlung der Opioidabhängigkeit im Justizvollzug“ wohnten etwa 200 Besucher*innen bei. Mit der wachsenden Verfügbarkeit des Buprenorphin-Depots in Justizvollzugsanstalten kann eine deutliche Annäherung an das geforderte Äquivalenzprinzip erreicht werden, so ein Fazit der Referate und nachfolgenden Diskussion. (Camurus, Mannheim/Lund, 13.12.2019)
https://www.buvidal.de/wp-content/uploads/2020/02/202012_Bericht_Symposium_Naeher_am_Aequivalenzprinzip_mit-Buprenorphin-Depot.pdf
Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: A randomized, double blind, placebo-controlled study.
Ahmadi J, Sarani EM, Jahromi MS.
Ci Ji Yi Xue Za Zhi. 2019 Mar 14;32(1):58-64. doi: 10.4103/tcmj.tcmj_220_18.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015018/
Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial.
Zamani N, Buckley NA, Hassanian-Moghaddam H.
Crit Care. 2020 Feb 7;24(1):44. doi: 10.1186/s13054-020-2740-y.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006192/
Sexual dysfunction in men on buprenorphine - naloxone-based substitution therapy.
Mattoo SK, Ghosh A, Subodh BN, Basu D, Satapathy A, Prasad S, Sharma MP.
Indian J Psychiatry. 2020 Jan-Feb;62(1):66-72. doi: 10.4103/psychiatry.IndianJPsychiatry_195_19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964450/
Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management.
Osborne V, Davies M, Roy D, Tescione F, Shakir SAW.
BMJ Evid Based Med. 2020 Feb 24. pii: bmjebm-2019-111295. doi: 10.1136/bmjebm-2019-111295.
https://ebm.bmj.com/content/early/2020/02/24/bmjebm-2019-111295.long
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM.
JAMA Netw Open. 2020 Feb 5;3(2):e1920622. doi: 10.1001/jamanetworkopen.2019.20622.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2760032
Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
Larance, B., Degenhardt, L., Grebely, J., Nielsen, S., Bruno, R., Dietze, P., Lancaster, K., Larney, S., Santo, T., Shanahan, M., Memedovic, S., Ali, R., and Farrell, M. ( 2020)
Addiction, doi.org/10.1111/add.14941.
https://onlinelibrary.wiley.com/doi/full/10.1111/add.14941
Abuses of FDA Regulatory Procedures - The Case of Suboxone.
Haffajee RL, Frank RG.
N Engl J Med. 2020 Feb 6;382(6):496-498. doi: 10.1056/NEJMp1906680.
The manufacturer of brand-name buprenorphine products exploited various FDA regulatory procedures to impede market entry of generic competitors and to maintain high prices. This case provides an example of the kinds of abuses that are common in prescription-drug markets.
Abstract
https://www.nejm.org/doi/full/10.1056/NEJMp1906680
Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study.
Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C.
J Subst Abuse Treat. 2020 Mar;110:1-8. doi: 10.1016/j.jsat.2019.11.004.
https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(19)30168-0/fulltext
Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach.
Rozylo J, Mitchell K, Nikoo M, Durante SE, Barbic SP, Lin D, Mathias S, Azar P.
Addict Sci Clin Pract. 2020 Jan 15;15(1):2. doi: 10.1186/s13722-020-0177-x.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964069/
Early-Career and Graduating Physicians More Likely to Prescribe Buprenorphine.
Peterson LE, Morgan ZJ, Eden AR.
J Am Board Fam Med. 2020 Jan-Feb;33(1):7-8. doi: 10.3122/jabfm.2020.01.190230.
https://www.jabfm.org/content/33/1/7.long
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Vierke C, Marxen B, Boettcher M, Hiemke C, Havemann-Reinecke U.
Eur Arch Psychiatry Clin Neurosci (2020). doi.org/10.1007/s00406-019-01091-0
https://link.springer.com/article/10.1007%2Fs00406-019-01091-0
Recurrent Use of Implantable Buprenorphine.
Campbell MC.
Prim Care Companion CNS Disord. 2019 Dec 5;21(6). pii: 19l02434. doi: 10.4088/PCC.19l02434.
https://www.psychiatrist.com/pcc/article/pages/2019/v21n06/19l02434.aspx
A Retrospective Survey of Buprenorphine Substitute Treatment With Minimal Dosage in Heroin Use Disorder.
Shen W, Wang Q, Zhang J, Ping W, Zhang J, Ye W, Hu Q, Cerci D, Zhou W.
Front Psychiatry. 2019 Dec 4;10:888. doi: 10.3389/fpsyt.2019.00888.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904327/
Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation.
Ling W, Shoptaw S, Goodman-Meza D.
Subst Abuse Rehabil. 2019 Nov 29;10:69-78. doi: 10.2147/SAR.S155843.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889966/
Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
Weicker SA, Hayashi K, Grant C, Milloy MJ, Wood E, Kerr T.
Drug Alcohol Depend. 2019 Dec 1;205:107672. doi: 10.1016/j.drugalcdep.2019.107672.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31706251
Synthetic Urines in a Buprenorphine Clinic.
Embers DM, Ravishankar DA, Din A, Sethi R.
Kans J Med. 2019 Nov 25;12(4):146-147. eCollection 2019 Nov.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884010/
Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine.
Chhabra N, Aks SE.
Am J Emerg Med. 2019 Nov 16. pii: S0735-6757(19)30627-8. doi: 10.1016/j.ajem.2019.09.014.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31753622
Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine.
Blue TR, Gordon MS, Schwartz RP, Couvillion K, Vocci FJ, Fitzgerald TT, O'Grady KE.
Addict Sci Clin Pract. 2019 Dec 2;14(1):45. doi: 10.1186/s13722-019-0172-2.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886176/
New…and improved? The latest studies on injectable buprenorphine for opioid use disorder
Suboxone is a first-line treatment for opioid use disorder. The need to take it daily, however, increases the risk that someone will miss a dose. Suboxone misuse and diversion also remain prominent concerns. Novel, FDA-approved injection formulations of buprenorphine, the active ingredient in Suboxone, were designed to address these potential drawbacks. Two recent studies show that injection buprenorphine outperforms a placebo injection and does as well as daily sublingual Suboxone. (Recovery Bulletin, USA, Dezember 2019)
https://www.recoveryanswers.org/research-post/monthly-injectable-buprenorphine/
Buprenorphin als Depot – Für stabile und instabile Patienten - Auf Buvidal® einstellen und erfolgreich Rituale aufbrechen
Mannheim/Lund, 4.12.2019 – Seit Februar 2019 können opioidabhängige Patienten*innen in Deutschland mit dem neuen Buprenorphin-Depot Buvidal® behandelt werden. Erfahrungen aus der Praxis zur Ein- und Umstellung auf das Depotpräparat wurden auf einem von der Camurus GmbH unterstützten Satellitensymposium im Rahmen des 28. Kongresses der Deutschen Gesellschaft für Suchtmedizin Anfang November 2019 in Berlin diskutiert. (Camurus, Schweden, Pressemitteilung, 04.12.2019)
Buvidal_Camurus_DGS Symposium Berlin November 2019
Opioid Substitution Treatment Using Buprenorphine for Management of Dependence on Natural Opioids: Case Series.
Kathiresan P, Ambekar A, Sarkar S.
Indian J Psychol Med. 2019 Nov 11;41(6):586-588. doi: 10.4103/IJPSYM.IJPSYM_62_19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875849/
Unusual Drug Test Results for a Patient on Buprenorphine and Naloxone.
Gall B, El-Khoury JM.
Clin Chem. 2019 Oct;65(10):1332-1333. doi: 10.1373/clinchem.2019.309484.
http://clinchem.aaccjnls.org/content/65/10/1332.long
Buprenorphine poisoning in children: a 10-year-experience of Marseille Poison Center.
von Fabeck K, Boulamery A, Glaizal M, de Haro L, Simon N.
Fundam Clin Pharmacol. 2019 Nov 1. doi: 10.1111/fcp.12518.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31675453
A comparison of sexual desire in opiate-dependent men receiving methadone and buprenorphine maintenance treatment.
Yee A, Loh HS, Loh HH, Riahi S, Ng CG, Sulaiman AHB.
Ann Gen Psychiatry. 2019 Oct 22;18:25. doi: 10.1186/s12991-019-0249-z.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805364/
Pharmacoeconomic Review Report: Buprenorphine extended-release injection (Sublocade): (Indivior Canada, Ltd.)
Indication: For the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jul.
https://www.ncbi.nlm.nih.gov/books/NBK546358/
CADTH Canadian Drug Expert Committee Recommendation: Buprenorphine (Sublocade — Indivior Canada Ltd.): Indication: Opioid use disorder [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun.
https://www.ncbi.nlm.nih.gov/books/NBK546256/
Acute Experimental Pain Responses in Methadone- and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study.
Murnion BP, Rivas C, Demirkol A, Hayes V, Lintzeris N, Nielsen S.
Pain Med. 2019 Aug 24. pii: pnz178. doi: 10.1093/pm/pnz178.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31504868
Anästhesievorbereitung: Welche Medikamente vor einer Narkose abgesetzt werden sollten
Schreiner, Mathias J.; Kehl, Franz
Dtsch Arztebl 2019; 116(31-32): A-1428 / B-1183 / C-1167
What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.
Vorspan F, Hjelmström P, Simon N, Benyamina A, Dervaux A, Brousse G, Jamain T, Kosim M, Rolland B.
Expert Opin Drug Deliv. 2019 Sep;16(9):907-914. doi: 10.1080/17425247.2019.1649252.
https://www.tandfonline.com/doi/full/10.1080/17425247.2019.1649252
Seite 1 von 9